[HTML][HTML] Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom …
HI Hurwitz, N Uppal, SA Wagner… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
HI Hurwitz, N Uppal, SA Wagner, JC Bendell, JT Beck, SM Wade III, JJ Nemunaitis, PJ Stella…
Journal of Clinical Oncology, 2015•ncbi.nlm.nih.govPurpose Patients with advanced pancreatic adenocarcinoma have a poor prognosis and
limited second-line treatment options. Evidence suggests a role for the Janus kinase
(JAK)/signal transducer and activator of transcription pathway in the pathogenesis and
clinical course of pancreatic cancer.
limited second-line treatment options. Evidence suggests a role for the Janus kinase
(JAK)/signal transducer and activator of transcription pathway in the pathogenesis and
clinical course of pancreatic cancer.
Abstract
Purpose
Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options. Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of transcription pathway in the pathogenesis and clinical course of pancreatic cancer.
ncbi.nlm.nih.gov